Verdemed brings affordable cannabinoid-based pharmaceuticals to doctors and patients in Latin America
Verdemed’s mission is to offer the best of approved existing and prospective cannabinoid products to all Latin Americans, in all countries, in all jurisdictions legally authorized to sell medical cannabis.
The company’s initial focus is on product formulations of cannabinoid pharmaceuticals currently available in Canada, Europe, and the USA. Verdemed aims to meet Latin America’s medical needs with similar products and medical cannabis treatments approved by Health Canada, EMA (European Medicines Agency), and the USA FDA (Food and Drug Administration).
Verdemed is uniquely positioned to tackle the high regulatory hurdles in Latin America with Canadian-derived pharmaceutical products.
Over the past 20 years, Canada has built a robust regulatory framework to protect patients’ safety and to secure reliable treatments with medical cannabis products. Most Latin American regulatory agencies have in place a regulatory regime similar to Canadian legislation around medical cannabis.
Verdemed leverages its Canadian DNA to offer high-end quality pharmaceuticals in Latin America.
This is where Verdemed is located. Learn more in our Operations page.
Verdemed supports #cbdlegal cause in Brazil
CBD involves science, health and hope.
This cause invites you to help us to communicate and explain the benefits of CBD. Join the #cbdlegal campaign.
(Video in Portuguese only)
Benzinga Capital Cannabis Conference April 2019
The Benzinga Cannabis Capital Conference is the premier gathering of cannabis entrepreneurs and investors in North America, connecting entrepreneurs hoping to build billion-dollar cannabis enterprises with investors whose capital can help make that happen.